Isarna Therapeutics, a privately held clinical stage biopharmaceutical company, has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic and fibrotic diseases and fight cancer.
The company advances a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.
Isarna Therapeutics has accumulated a vast amount of expertise and intellectual property by focusing its research and development efforts on targeting the transforming growth factor beta (TGF-β) pathway in high-medical-need diseases. The privately held, clinical stage biopharmaceutical company Isarna is established in the Netherlands, Germany (Munich), and the United States.
The company has developed a portfolio of compounds (antisense oligonucleotides) specifically designed to target the three different TGF-β isoforms (TGF-β1, TGF-β2, and TGF-β3) for the treatment of ophthalmic and fibrotic diseases and cancer. This expertise is unique in the world.